Haisco Pharmaceutical Group Co., Ltd.
002653
Rangering i aksjer
#2001
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Aksjekurs
$9.04
Markedsverdi
$10.31B
Endring (1 dag)
0.08%
Endring (1 år)
23.85%
Land
CN
Handel Haisco Pharmaceutical Group Co., Ltd. (002653)
Kategori
Healthcare
Inntekter for Haisco Pharmaceutical Group Co., Ltd. (002653)
Inntekter i Jun 2026 TTM: $794.50M
Ifølge de nyeste økonomiske rapportene til Haisco Pharmaceutical Group Co., Ltd. er selskapets nåværende inntekter (TTM) $794.50M. I 2023 hadde selskapet inntekter på $473.97M en økning sammenlignet med inntektene i 2022, som var $437.13M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Haisco Pharmaceutical Group Co., Ltd. fra 2008 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $794.50M | 55.83% |
| 2024 | $509.84M | 7.57% |
| 2023 | $473.97M | 8.43% |
| 2022 | $437.13M | 0.18% |
| 2021 | $436.34M | -14.39% |
| 2020 | $509.68M | -9.86% |
| 2019 | $565.44M | 13.51% |
| 2018 | $498.16M | 74.62% |
| 2017 | $285.29M | 37.97% |
| 2016 | $206.77M | 10.75% |
| 2015 | $186.71M | -4.47% |
| 2014 | $195.45M | 19.47% |
| 2013 | $163.60M | 27.19% |
| 2012 | $128.62M | 34.15% |
| 2011 | $95.88M | 8.81% |
| 2010 | $88.11M | 24.14% |
| 2009 | $70.98M | 36.50% |
| 2008 | $52.00M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 1,488.97% |
US
|
|
| $2.23B | 180.43% |
US
|
|
| $15.74B | 1,881.68% |
AU
|
|
| $6.02B | 657.88% |
NL
|
|
| - | - |
CH
|
